These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 38441767)

  • 1. Anti-CRISPR Proteins and Their Application to Control CRISPR Effectors in Mammalian Systems.
    Gebhardt CM; Niopek D
    Methods Mol Biol; 2024; 2774():205-231. PubMed ID: 38441767
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Potent Cas9 Inhibition in Bacterial and Human Cells by AcrIIC4 and AcrIIC5 Anti-CRISPR Proteins.
    Lee J; Mir A; Edraki A; Garcia B; Amrani N; Lou HE; Gainetdinov I; Pawluk A; Ibraheim R; Gao XD; Liu P; Davidson AR; Maxwell KL; Sontheimer EJ
    mBio; 2018 Dec; 9(6):. PubMed ID: 30514786
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-CRISPR proteins targeting the CRISPR-Cas system enrich the toolkit for genetic engineering.
    Liu Q; Zhang H; Huang X
    FEBS J; 2020 Feb; 287(4):626-644. PubMed ID: 31730297
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Type II anti-CRISPR proteins as a new tool for synthetic biology.
    Zhang Y; Marchisio MA
    RNA Biol; 2021 Aug; 18(8):1085-1098. PubMed ID: 32991234
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Applications of Anti-CRISPR Proteins in Genome Editing and Biotechnology.
    Kraus C; Sontheimer EJ
    J Mol Biol; 2023 Jul; 435(13):168120. PubMed ID: 37100169
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Functional Features and Current Applications of the RNA-Targeting Type VI CRISPR-Cas Systems.
    Perčulija V; Lin J; Zhang B; Ouyang S
    Adv Sci (Weinh); 2021 Jul; 8(13):2004685. PubMed ID: 34254038
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bioinformatics Identification of Anti-CRISPR Loci by Using Homology, Guilt-by-Association, and CRISPR Self-Targeting Spacer Approaches.
    Yin Y; Yang B; Entwistle S
    mSystems; 2019 Sep; 4(5):. PubMed ID: 31506266
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In Silico Approaches for Prediction of Anti-CRISPR Proteins.
    Makarova KS; Wolf YI; Koonin EV
    J Mol Biol; 2023 Apr; 435(7):168036. PubMed ID: 36868398
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition mechanisms of CRISPR-Cas9 by AcrIIA17 and AcrIIA18.
    Wang X; Li X; Ma Y; He J; Liu X; Yu G; Yin H; Zhang H
    Nucleic Acids Res; 2022 Jan; 50(1):512-521. PubMed ID: 34893860
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Non-canonical inhibition strategies and structural basis of anti-CRISPR proteins targeting type I CRISPR-Cas systems.
    Yin P; Zhang Y; Yang L; Feng Y
    J Mol Biol; 2023 Apr; 435(7):167996. PubMed ID: 36754343
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chemistry of Class 1 CRISPR-Cas effectors: Binding, editing, and regulation.
    Liu TY; Doudna JA
    J Biol Chem; 2020 Oct; 295(42):14473-14487. PubMed ID: 32817336
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Widespread anti-CRISPR proteins in virulent bacteriophages inhibit a range of Cas9 proteins.
    Hynes AP; Rousseau GM; Agudelo D; Goulet A; Amigues B; Loehr J; Romero DA; Fremaux C; Horvath P; Doyon Y; Cambillau C; Moineau S
    Nat Commun; 2018 Jul; 9(1):2919. PubMed ID: 30046034
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A comprehensive appraisal of mechanism of anti-CRISPR proteins: an advanced genome editor to amend the CRISPR gene editing.
    Choudhary N; Tandi D; Verma RK; Yadav VK; Dhingra N; Ghosh T; Choudhary M; Gaur RK; Abdellatif MH; Gacem A; Eltayeb LB; Alqahtani MS; Yadav KK; Jeon BH
    Front Plant Sci; 2023; 14():1164461. PubMed ID: 37426982
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An enhanced assay to characterize anti-CRISPR proteins using a cell-free transcription-translation system.
    Wandera KG; Collins SP; Wimmer F; Marshall R; Noireaux V; Beisel CL
    Methods; 2020 Feb; 172():42-50. PubMed ID: 31121300
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-CRISPRs: Protein Inhibitors of CRISPR-Cas Systems.
    Davidson AR; Lu WT; Stanley SY; Wang J; Mejdani M; Trost CN; Hicks BT; Lee J; Sontheimer EJ
    Annu Rev Biochem; 2020 Jun; 89():309-332. PubMed ID: 32186918
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Structure-based functional mechanisms and biotechnology applications of anti-CRISPR proteins.
    Jia N; Patel DJ
    Nat Rev Mol Cell Biol; 2021 Aug; 22(8):563-579. PubMed ID: 34089013
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Exploitation of the Cooperative Behaviors of Anti-CRISPR Phages.
    Chevallereau A; Meaden S; Fradet O; Landsberger M; Maestri A; Biswas A; Gandon S; van Houte S; Westra ER
    Cell Host Microbe; 2020 Feb; 27(2):189-198.e6. PubMed ID: 31901522
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structural and mechanistic insights into the inhibition of type I-F CRISPR-Cas system by anti-CRISPR protein AcrIF23.
    Ren J; Wang H; Yang L; Li F; Wu Y; Luo Z; Chen Z; Zhang Y; Feng Y
    J Biol Chem; 2022 Jul; 298(7):102124. PubMed ID: 35697070
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Structural basis for AcrVA4 inhibition of specific CRISPR-Cas12a.
    Knott GJ; Cress BF; Liu JJ; Thornton BW; Lew RJ; Al-Shayeb B; Rosenberg DJ; Hammel M; Adler BA; Lobba MJ; Xu M; Arkin AP; Fellmann C; Doudna JA
    Elife; 2019 Aug; 8():. PubMed ID: 31397669
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Types I and V Anti-CRISPR Proteins: From Phage Defense to Eukaryotic Synthetic Gene Circuits.
    Yu L; Marchisio MA
    Front Bioeng Biotechnol; 2020; 8():575393. PubMed ID: 33102460
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.